Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of human exogenous DNA on production of perforin-containing CD8+ cytotoxic lymphocytes in laboratory setting and clinical practice.
Alyamkina EA, Leplina OY, Ostanin AA, Chernykh ER, Nikolin VP, Popova NA, Proskurina AS, Gvozdeva TS, Dolgova EV, Orishchenko KE, Rogachev VA, Sidorov SV, Varaksin NA, Ryabicheva TG, Bogachev SS, Shurdov MA. Alyamkina EA, et al. Among authors: sidorov sv. Cell Immunol. 2012 Mar-Apr;276(1-2):59-66. doi: 10.1016/j.cellimm.2012.04.004. Epub 2012 Apr 7. Cell Immunol. 2012. PMID: 22578800
A strategy of tumor treatment in mice with doxorubicin-cyclophosphamide combination based on dendritic cell activation by human double-stranded DNA preparation.
Alyamkina EA, Nikolin VP, Popova NA, Dolgova EV, Proskurina AS, Orishchenko KE, Efremov YR, Chernykh ER, Ostanin AA, Sidorov SV, Ponomarenko DM, Zagrebelniy SN, Bogachev SS, Shurdov MA. Alyamkina EA, et al. Among authors: sidorov sv. Genet Vaccines Ther. 2010 Nov 1;8:7. doi: 10.1186/1479-0556-8-7. Genet Vaccines Ther. 2010. PMID: 21040569 Free PMC article.
Results of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancer.
Proskurina AS, Gvozdeva TS, Alyamkina EA, Dolgova EV, Orishchenko KE, Nikolin VP, Popova NA, Sidorov SV, Chernykh ER, Ostanin AA, Leplina OY, Dvornichenko VV, Ponomarenko DM, Soldatova GS, Varaksin NA, Ryabicheva TG, Uchakin PN, Zagrebelniy SN, Rogachev VA, Bogachev SS, Shurdov MA. Proskurina AS, et al. Among authors: sidorov sv. BMC Cancer. 2015 Mar 13;15:122. doi: 10.1186/s12885-015-1142-z. BMC Cancer. 2015. PMID: 25886605 Free PMC article. Clinical Trial.
Erratum to: Results of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancer.
Proskurina AS, Gvozdeva TS, Alyamkina EA, Dolgova EV, Orishchenko KE, Nikolin VP, Popova NA, Sidorov SV, Chernykh ER, Ostanin AA, Leplina OY, Dvornichenko VV, Ponomarenko DM, Soldatova GS, Varaksin NA, Ryabicheva TG, Uchakin PN, Zagrebelniy SN, Rogachev VA, Bogachev SS, Shurdov MA. Proskurina AS, et al. Among authors: sidorov sv. BMC Cancer. 2016 Feb 17;16:117. doi: 10.1186/s12885-016-2163-y. BMC Cancer. 2016. PMID: 26887451 Free PMC article. No abstract available.
Five-year disease-free survival among stage II-IV breast cancer patients receiving FAC and AC chemotherapy in phase II clinical trials of Panagen.
Proskurina AS, Gvozdeva TS, Potter EA, Dolgova EV, Orishchenko KE, Nikolin VP, Popova NA, Sidorov SV, Chernykh ER, Ostanin AA, Leplina OY, Dvornichenko VV, Ponomarenko DM, Soldatova GS, Varaksin NA, Ryabicheva TG, Uchakin PN, Rogachev VA, Shurdov MA, Bogachev SS. Proskurina AS, et al. Among authors: sidorov sv. BMC Cancer. 2016 Aug 18;16:651. doi: 10.1186/s12885-016-2711-5. BMC Cancer. 2016. PMID: 27538465 Free PMC article. Clinical Trial.
[Cytokine production by blood immune cells, tumor and its microenvironment, characteristic of extracellular matrix in patients with invasive ductal carcinoma of no special type].
Autenshlyus AI, Davletova KI, Studenikina AA, Mikhaylova ES, Varaksin NA, Zhurakovsky IP, Proskura AV, Sidorov SV, Lyakhovich VV. Autenshlyus AI, et al. Among authors: sidorov sv. Biomed Khim. 2019 Aug;65(5):424-431. doi: 10.18097/PBMC20196505424. Biomed Khim. 2019. PMID: 31666416 Russian.
Approbation of the Cancer Treatment Approach Based on the Eradication of TAMRA+ Cancer Stem Cells in a Model of Murine Cyclophosphamide Resistant Lymphosarcoma.
Kisaretova PE, Kirikovich SS, Ritter GS, Efremov YR, Taranov OS, Dubatolova TD, Proskurina AS, Potter EA, Dolgova EV, Sidorov SV, Ostanin AA, Chernykh ER, Bogachev SS. Kisaretova PE, et al. Among authors: sidorov sv. Anticancer Res. 2020 Feb;40(2):795-805. doi: 10.21873/anticanres.14011. Anticancer Res. 2020. PMID: 32014922
Personalized Approach to Determination of Histidine-Rich Glycoprotein and E-Cadherin in Supernatants of Immunocompetent Blood Cells and Breast Biopsy Specimens in Breast Malignant and Non-Malignant Disease.
Autenshlyus AI, Bernado AV, Studenikina AA, Proskura AV, Davletova KI, Zhurakovskiy IP, Arkhipov SA, Varaksin NA, Sidorov SV, Lyakhovich VV. Autenshlyus AI, et al. Among authors: sidorov sv. Dokl Biochem Biophys. 2020 Jan;490(1):1-4. doi: 10.1134/S1607672920010019. Epub 2020 Apr 27. Dokl Biochem Biophys. 2020. PMID: 32342301
34 results